Antlia Bioscience is a preclinical biotechnology company in Encinitas, California developing novel long-acting therapeutics for chronic cardiometabolic diseases. Its approach centers on peptide-based therapies for cardiovascular and metabolic conditions, extended in half-life so they can be dosed practically. In 2020 it announced a strategic alliance with XL-protein GmbH to apply that company's PASylation half-life-extension technology to a long-acting peptide treatment for chronic heart failure. The company was incorporated in 2020 and remains a small, privately held research-stage organization.